Session 9: Primary and adjuvant systemic therapy of early breast cancer: Estimating the magnitude of clinical benefit I
Chairs: Daniel F. Hayes (USA), Karen Gelmon (Canada)
- Adjuvant and neoadjuvant chemotherapy in patients with ER positive and HER2 negative breast cancer (Angelo Di Leo, Italy)
- Adjuvant endocrine therapy for premenopausal women: Risk stratification, type and duration (Prudence Francis, Australia)
- Adjuvant endocrine therapy in postmenopausal women: Risk stratification, type and duration (Harold J. Burstein, USA)
- Estimating the magnitude of clinical benefit of bisphosphonates and denosumab in the adjuvant setting (Robert Coleman, UK)
BCC2019 PARTICIPANT: PASSWORD in BCC e-mail from March 23.